



# PROVIDER *bulletin*

April 2, 2020

Dear Provider:

Please be aware of the notice from the FDA regarding ranitidine products. The release may be found at the link.

[https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market?utm\\_campaign=FDA%20Requests%20Removal%20of%20All%20Ranitidine%20Products%20%28Zantac%29%20from%20the%20Market&utm\\_medium=email&utm\\_source=Eloqua](https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market?utm_campaign=FDA%20Requests%20Removal%20of%20All%20Ranitidine%20Products%20%28Zantac%29%20from%20the%20Market&utm_medium=email&utm_source=Eloqua)

Two points of emphasis the FDA recommend patients and consumers not to take the medications to drug take back centers, but rather follow the instructions to safely dispose at home as found in the medication guide or package insert, and not to abruptly stop therapy without consulting their physician.

For members needing stomach acid reducing therapies, KFHC has famotidine available as well as PPIs such as omeprazole and pantoprazole. Please note that most regimens, Heartburn, GERD, H pylori, and treatment of most ulcer and esophagitis conditions are suggested for short term use. Only the maintenance therapy and treatment of hypersecretory conditions require long term use. This may be a good opportunity to evaluate if de-prescribing is warranted. More information regarding appropriate treatment may be found at this link.

<https://www.medscape.com/viewarticle/923739>

Sincerely,

Bruce Wearda, R.Ph.  
Director of Pharmacy